In this paper, we will not cover the edoxaban experience in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial in detail given that the primary results have just recently been published. This evidence concerns the gene F10 and atrial fibrillation.